Loomis Sayles & Co. L P Has $566.34 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Loomis Sayles & Co. L P lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,342,740 shares of the life sciences company’s stock after selling 119,254 shares during the quarter. Illumina accounts for approximately 0.7% of Loomis Sayles & Co. L P’s investment portfolio, making the stock its 29th biggest position. Loomis Sayles & Co. L P owned about 2.74% of Illumina worth $566,337,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. O Shaughnessy Asset Management LLC raised its position in shares of Illumina by 91.7% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,199 shares of the life sciences company’s stock valued at $577,000 after buying an additional 2,009 shares in the last quarter. SVB Wealth LLC lifted its stake in shares of Illumina by 6.8% in the 1st quarter. SVB Wealth LLC now owns 3,277 shares of the life sciences company’s stock valued at $450,000 after acquiring an additional 209 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Illumina by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 253,629 shares of the life sciences company’s stock valued at $34,828,000 after acquiring an additional 1,064 shares in the last quarter. Motley Fool Asset Management LLC grew its position in Illumina by 8.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 4,688 shares of the life sciences company’s stock worth $644,000 after acquiring an additional 374 shares during the last quarter. Finally, Tidal Investments LLC increased its holdings in Illumina by 51.2% in the 1st quarter. Tidal Investments LLC now owns 9,901 shares of the life sciences company’s stock worth $1,361,000 after purchasing an additional 3,352 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ILMN shares. Piper Sandler reduced their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Barclays lifted their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Scotiabank reduced their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. Daiwa America raised shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. Finally, TD Cowen lifted their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Stock Performance

Shares of ILMN opened at $140.14 on Monday. Illumina, Inc. has a fifty-two week low of $93.51 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business has a 50-day moving average of $140.61 and a 200 day moving average of $124.94.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 earnings per share. Analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.